Delgado Sigfrido 4/A

What Happened Sigfrido Delgado, Senior Vice President, Operations at Avanos Medical (AVNS), received equity awards on March 13, 2026: 15,886 time‑based restricted share units (TRSUs) and 37,520 derivative TRSUs. Both awards were granted at $0.00 (no cash paid). These are awards/grants (transaction code A), not open‑market purchases or sales.

Key Details

• Transaction date: March 13, 2026; reported via an amended Form 4/A filed April 1, 2026 (this amendment corrects an earlier Form 4/A that had an erroneous option count; the original Form 4 filed March 17, 2026 was correct).
• Award amounts: 15,886 TRSUs (F1) and 37,520 derivative TRSUs (F2); acquisition price $0.00 for both.
• Vesting (per footnotes):
  • 15,886 TRSUs vest 1/3 on Mar 13, 2027; 1/3 on Mar 13, 2028; 1/3 on Mar 13, 2029 (F1).
  • 37,520 award vests 30% on Mar 13, 2027; 30% on Mar 13, 2028; 40% on Mar 13, 2029 (F2).
• Shares owned after the reported transaction: not disclosed on this filing.
• Filing timeliness: The transaction occurred 2026-03-13; the original Form 4 was filed 2026-03-17 and this correcting Form 4/A was filed 2026-04-01 — both filings are after the transaction date.

Context

• TRSUs are restricted share units that represent the economic equivalent of one share and convert to (or pay the value of) common stock when they vest; these are time‑based grants and do not indicate an immediate sale or cash transaction.
• This filing amends prior reporting to correct an erroneous addition of stock options; it does not report any option exercises, sales, or purchases by the reporting person.